Cooley advised Janux Therapeutics, and Wilson Sonsini Goodrich & Rosati advised the company on patent matters related to the transaction, while Latham & Watkins advised the...
Janux Therapeutics’ $350 Million Common Stock Offering
Monte Rosa Therapeutics’ $100 Million Underwritten Public Offering
Goodwin Procter advised Monte Rosa Therapeutics, while Paul Hastings advised TD Cowen and Wedbush PacGrow, as joint book-running managers, in the offering. Monte Rosa Therapeutics, Inc....
PepGen’s $108 Million Initial Public Offering
Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
Omega Therapeutics’ $144.6 Million IPO
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...